Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28950292 | 0.89 | CYP19A1 (0.55) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL27625009 | 0.85 | MAOA (0.51) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL1170732 | 0.81 | PDE5A (0.78) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL15361080 | 0.81 | CYP3A4 (0.65) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL31571483 | 0.80 | CYP3A4 (0.59) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL7651618 | 0.80 | CYP3A4 (0.59) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL15899627 | 0.79 | ABCG2 (0.54) | ABCB1CYP19A1CYP3A4PDE5AKDM1A | |
| SCHEMBL30999872 | 0.78 | CYP19A1 (0.63) | ABCB1CYP19A1PTPN1PDE5AMGAM | |
| SCHEMBL5072293 | 0.77 | MGAM (0.74) | ABCB1CYP19A1CYP3A4PTPN1PDE5A | |
| SCHEMBL8541548 | 0.74 | MAPT (0.64) | ABCB1CYP19A1CYP3A4MAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572781-B2 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA (US) | 2009-08-11 | — | — | US | disclosed |
| US-7534779-B2 | a steroidal quinol that is converted to a biologically active estrogen compound via enzyme catalyzed reduction; 2-(1-adamantyl)-estra-1,3,5(10)-triene-3,17 beta -diol; estrogen receptors activator; low lipid solubility; cataract, glaucoma, conjunctivitis, diabetic retinopathy | UNIVERSITY OF FLORIDA (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080119446-A1 | Prodrugs for Use as Ophthalmic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-22 | — | — | US | disclosed |
| US-20070213310-A1 | Prodrugs for Use as Ophthalmic Agents | PROKAI LASZLO | 2007-09-13 | — | — | US | disclosed |
| US-20070155711-A1 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2007-07-05 | — | — | US | disclosed |
| US-7186707-B2 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1569648-A4 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | UNIV FLORIDA (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1003522-B1 | USE OF ESTROGEN FOR PREVENTING OR CONTROLLING CATARACT | UNIV SYDNEY (AU) | 2005-11-16 | — | — | EP | disclosed |
| EP-1569648-A1 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | University of Florida (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040171596-A1 | Prodrugs for use as ophthalmic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2004-09-02 | — | — | US | disclosed |
| WO-2004069248-A1 | PRODRUGS FOR USE A OPHTHALMIC AGENTS | UNIVERSITY OF FLORIDA (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-1003522-A4 | A METHOD FOR PREVENTING OR CONTROLLING CATARACT | UNIV SYDNEY (AU) | 2002-05-02 | — | — | EP | disclosed |
| US-6258856-B1 | ADMINISTERING ESTROGEN FOR CATARACT PREVENTION | THE UNIVERSITY OF SYDNEY (AU) | 2001-07-10 | — | — | US | disclosed |
| EP-1003522-A1 | A METHOD FOR PREVENTING OR CONTROLLING CATARACT | THE UNIVERSITY OF SYDNEY (AU) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998026784-A1 | A METHOD FOR PREVENTING OR CONTROLLING CATARACT | THE UNIVERSITY OF SYDNEY (AU) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171596-A1 | Prodrugs for use as ophthalmic agents | CYP21A2, CYP19A1, CYP17A1 | ABCB1 110/4885CYP19A1 2/4885CYP3A4 137/4885 |
| US-20070155711-A1 | Prodrugs for use as ophthalmic agents | CYP19A1, CYP21A2, CYP17A1 | ABCB1 60/4885CYP19A1 1/4885CYP3A4 109/4885 |
| US-20080119446-A1 | Prodrugs for Use as Ophthalmic Agents | CYP21A2, CYP19A1, CYP17A1 | ABCB1 119/4885CYP19A1 2/4885CYP3A4 135/4885 |
| US-20070213310-A1 | Prodrugs for Use as Ophthalmic Agents | CYP21A2, CYP19A1, CYP17A1 | ABCB1 110/4885CYP19A1 2/4885CYP3A4 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.